Shares of Tesaro Inc. (NASDAQ:TSRO) have received an average rating of “Buy” from the sixteen research firms that are presently covering the stock. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $119.12.

Several research firms recently commented on TSRO. Royal Bank Of Canada began coverage on shares of Tesaro in a report on Friday, August 12th. They set an “outperform” rating and a $122.00 target price on the stock. FBR & Co increased their target price on shares of Tesaro from $115.00 to $133.00 and gave the company an “outperform” rating in a report on Friday, November 4th. Wedbush reaffirmed a “buy” rating on shares of Tesaro in a report on Friday, August 5th. RBC Capital Markets increased their target price on shares of Tesaro from $122.00 to $128.00 and gave the company an “outperform” rating in a report on Monday, October 10th. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $150.00 target price (up previously from $114.00) on shares of Tesaro in a report on Monday, November 7th.

Tesaro (NASDAQ:TSRO) traded up 1.833% during midday trading on Friday, reaching $140.255. 328,593 shares of the company’s stock traded hands. The stock’s market cap is $7.25 billion. Tesaro has a 52-week low of $29.51 and a 52-week high of $148.74. The company’s 50-day moving average price is $122.09 and its 200-day moving average price is $87.79.

Tesaro (NASDAQ:TSRO) last released its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.98) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.92) by $0.06. Tesaro had a negative net margin of 798.68% and a negative return on equity of 141.88%. The business had revenue of $3.73 million for the quarter, compared to the consensus estimate of $4.39 million. During the same period in the prior year, the business posted ($1.66) EPS. Tesaro’s revenue for the quarter was up 4187.4% on a year-over-year basis. On average, equities analysts predict that Tesaro will post ($7.42) EPS for the current fiscal year.

In related news, VP Jeffrey H. Hanke sold 29,166 shares of Tesaro stock in a transaction dated Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the completion of the transaction, the vice president now directly owns 29,166 shares of the company’s stock, valued at approximately $2,509,442.64. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Martin H. Jr. Huber sold 327 shares of Tesaro stock in a transaction dated Wednesday, November 2nd. The shares were sold at an average price of $121.29, for a total transaction of $39,661.83. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $223,416.18. The disclosure for this sale can be found here. Corporate insiders own 40.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of TSRO. FMR LLC boosted its position in shares of Tesaro by 9.6% in the second quarter. FMR LLC now owns 6,097,449 shares of the biopharmaceutical company’s stock worth $512,490,000 after buying an additional 531,892 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Tesaro by 16.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 5,584,279 shares of the biopharmaceutical company’s stock worth $559,768,000 after buying an additional 776,709 shares in the last quarter. Vanguard Group Inc. raised its stake in Tesaro by 11.0% in the second quarter. Vanguard Group Inc. now owns 2,216,739 shares of the biopharmaceutical company’s stock worth $186,317,000 after buying an additional 219,902 shares in the last quarter. BlackRock Fund Advisors raised its stake in Tesaro by 9.6% in the third quarter. BlackRock Fund Advisors now owns 1,533,499 shares of the biopharmaceutical company’s stock worth $153,718,000 after buying an additional 133,790 shares in the last quarter. Finally, State Street Corp raised its stake in Tesaro by 12.9% in the second quarter. State Street Corp now owns 1,008,667 shares of the biopharmaceutical company’s stock worth $84,777,000 after buying an additional 114,918 shares in the last quarter. 90.42% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/25/tesaro-inc-tsro-given-average-rating-of-buy-by-brokerages.html.

About Tesaro

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Stock Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related stocks with our FREE daily email newsletter.